Overview

* Vir Q2 revenue of $1.2 mln missed analyst expectations, per LSEG data

* Net loss for Q2 was $111 mln, or $0.80 per share, narrows yr/yr

* Company maintains strong cash position with $892.1 mln, runway into mid-2027

Outlook

* Vir expects cash to fund operations into mid-2027

Result Drivers

* COST SAVINGS - Reduction in R&D and SG&A expenses attributed to restructuring initiatives

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $1.20 $2.72

Revenue mln mln (6

Analysts

)

Q2 EPS -$0.8

Q2 Net -$111

Income mln

Q2 Cash $892.10

& mln

Investme

nts

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Vir Biotechnology Inc ( VIR ) is $15.50, about 67% above its August 5 closing price of $5.11

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)